JMP Securities upgraded Sabra Health Care (SBRA) to Outperform from Market Perform with a $20 price target The firm expects “multiple tailwinds to result in outsized returns” for the stock. Sabra will have a “unique and value-creating year” in 2025 for multiple reasons, including its tenant operating troubles related to the pandemic being functionally over, the analyst tells investors in a research note. Further, JMP says the company’s skilled nursing rent coverage ratios should continue to expand given the reporting methodology and a strong Medicaid rate environment. Third, Sabra’s senior housing assets are poised for multi-year growth due to a significant shortfall of development, contends the firm.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SBRA:
- Sabra Health Care price target lowered to $20 from $21 at Jefferies
- Sabra Health Care downgraded to Neutral from Outperform at Mizuho
- Sabra Health Care price target raised to $21 from $20 at BofA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
